ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol
June 16, 2021Avenue Therapeutics, focused on the development of intravenous (IV) tramadol for the US market, announced that it has received a second Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application ... -
Avenue Therapeutics Announces NDA Submission for IV Tramadol
December 17, 2019Avenue Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to ... -
Avenue Announces Positive Phase 3 Trial Results
May 22, 2018Avenue Therapeutics announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement
Pharma Sources Insight January 2025
